These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38197578)

  • 21. Adherence and persistence to urate-lowering therapies in the Irish setting.
    McGowan B; Bennett K; Silke C; Whelan B
    Clin Rheumatol; 2016 Mar; 35(3):715-21. PubMed ID: 25409858
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Allopurinol: insights from studies of dose-response relationships.
    Day RO; Kannangara DR; Stocker SL; Carland JE; Williams KM; Graham GG
    Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):449-462. PubMed ID: 27927043
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Myeloperoxidase and oxidation of uric acid in gout: implications for the clinical consequences of hyperuricaemia.
    Stamp LK; Turner R; Khalilova IS; Zhang M; Drake J; Forbes LV; Kettle AJ
    Rheumatology (Oxford); 2014 Nov; 53(11):1958-65. PubMed ID: 24899662
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Allopurinol-induced DRESS syndrome.
    Markel A
    Isr Med Assoc J; 2005 Oct; 7(10):656-60. PubMed ID: 16259349
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease.
    Panomvana D; Sripradit S; Angthararak S
    J Clin Rheumatol; 2008 Feb; 14(1):6-11. PubMed ID: 18431090
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The population pharmacokinetics of allopurinol and oxypurinol in patients with gout.
    Wright DF; Stamp LK; Merriman TR; Barclay ML; Duffull SB; Holford NH
    Eur J Clin Pharmacol; 2013 Jul; 69(7):1411-21. PubMed ID: 23475133
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allergic reaction to allopurinol with cross-reactivity to oxypurinol.
    Lockard O; Harmon C; Nolph K; Irvin W
    Ann Intern Med; 1976 Sep; 85(3):333-5. PubMed ID: 134655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adherence and Outcomes with Urate-Lowering Therapy: A Site-Randomized Trial.
    Mikuls TR; Cheetham TC; Levy GD; Rashid N; Kerimian A; Low KJ; Coburn BW; Redden DT; Saag KG; Foster PJ; Chen L; Curtis JR
    Am J Med; 2019 Mar; 132(3):354-361. PubMed ID: 30503879
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allopurinol and kidney function: An update.
    Stamp LK; Chapman PT; Palmer SC
    Joint Bone Spine; 2016 Jan; 83(1):19-24. PubMed ID: 26453097
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allopurinol use and type 2 diabetes incidence among patients with gout: A VA retrospective cohort study.
    Slobodnick A; Toprover M; Greenberg J; Crittenden DB; Pike VC; Qian Y; Zhong H; Pillinger MH
    Medicine (Baltimore); 2020 Aug; 99(35):e21675. PubMed ID: 32871882
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD).
    Mikuls TR; Farrar JT; Bilker WB; Fernandes S; Saag KG
    Rheumatology (Oxford); 2005 Aug; 44(8):1038-42. PubMed ID: 15870145
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oxypurinol, allopurinol and allopurinol-1-riboside in plasma following an acute overdose of allopurinol in a patient with advanced chronic kidney disease.
    Kannangara DR; Roberts DM; Furlong TJ; Graham GG; Williams KM; Day RO
    Br J Clin Pharmacol; 2012 May; 73(5):828-9. PubMed ID: 22098112
    [No Abstract]   [Full Text] [Related]  

  • 33. Achieving serum urate targets in gout: an audit in a gout-oriented rheumatology practice.
    Corbett EJM; Pentony P; McGill NW
    Int J Rheum Dis; 2017 Jul; 20(7):894-897. PubMed ID: 28205336
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationships Between Allopurinol Dose, Oxypurinol Concentration and Urate-Lowering Response-In Search of a Minimum Effective Oxypurinol Concentration.
    Stamp LK; Chapman PT; Barclay M; Horne A; Frampton C; Merriman TR; Wright DFB; Drake J; Dalbeth N
    Clin Transl Sci; 2020 Jan; 13(1):110-115. PubMed ID: 31444839
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment.
    Stamp LK; O'Donnell JL; Zhang M; James J; Frampton C; Barclay ML; Chapman PT
    Arthritis Rheum; 2011 Feb; 63(2):412-21. PubMed ID: 21279998
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adherence with urate-lowering therapies for the treatment of gout.
    Harrold LR; Andrade SE; Briesacher BA; Raebel MA; Fouayzi H; Yood RA; Ockene IS
    Arthritis Res Ther; 2009; 11(2):R46. PubMed ID: 19327147
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gout: Why compare the effectiveness of suboptimal gout management?
    Dalbeth N; Stamp LK
    Nat Rev Rheumatol; 2015 Sep; 11(9):506-7. PubMed ID: 26150126
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Allopurinol versus rilonacept for the prevention of gout flares: comment on the article by Schumacher et al.
    Meltzer M
    Arthritis Care Res (Hoboken); 2013 May; 65(5):838. PubMed ID: 23281274
    [No Abstract]   [Full Text] [Related]  

  • 39. Estimation of adherence to urate-lowering therapy in people living with gout using Australia's Pharmaceutical Benefits Scheme and patient-reported dosing.
    Schulz M; Coleshill MJ; Day RO; Wright DFB; Brett J; Briggs NE; Aung E
    Br J Clin Pharmacol; 2024 May; 90(5):1322-1332. PubMed ID: 38382554
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Cardiovascular risk in gout - Role of allopurinol?].
    de Jong ICA; van Herwaarden N; Rongen GA; van der Pol KH
    Ned Tijdschr Geneeskd; 2021 Apr; 165():. PubMed ID: 33914423
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.